Clean Yield Group Cut Gilead Sciences Com (GILD) Holding By $329,751; 6 Analysts Bullish UBS Group AG (UBS)

Clean Yield Group decreased Gilead Sciences Inc Com (GILD) stake by 7.85% reported in 2017Q3 SEC filing. Clean Yield Group sold 4,071 shares as Gilead Sciences Inc Com (GILD)’s stock declined 8.05%. The Clean Yield Group holds 47,762 shares with $3.87 million value, down from 51,833 last quarter. Gilead Sciences Inc Com now has $105.74B valuation. The stock increased 0.81% or $0.65 during the last trading session, reaching $80.72. About 7.03M shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since March 12, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Among 12 analysts covering UBS AG (NYSE:UBS), 6 have Buy rating, 0 Sell and 6 Hold. Therefore 50% are positive. UBS AG had 21 analyst reports since September 15, 2015 according to SRatingsIntel. The stock of UBS Group AG (NYSE:UBS) has “Neutral” rating given on Tuesday, September 15 by Goldman Sachs. On Tuesday, June 28 the stock rating was downgraded by RBC Capital Markets to “Underperform”. RBC Capital Markets downgraded the shares of UBS in report on Wednesday, February 3 to “Sector Perform” rating. On Wednesday, January 11 the stock rating was upgraded by Societe Generale to “Buy”. The firm has “Buy” rating by Bank of America given on Friday, November 10. The company was upgraded on Tuesday, December 6 by Morgan Stanley. The stock of UBS Group AG (NYSE:UBS) has “Neutral” rating given on Tuesday, February 7 by Bank of America. Bank of America downgraded UBS Group AG (NYSE:UBS) on Tuesday, November 3 to “Underperform” rating. Macquarie Research downgraded the stock to “Neutral” rating in Wednesday, February 24 report. The stock of UBS Group AG (NYSE:UBS) has “Hold” rating given on Friday, May 13 by Societe Generale. See UBS Group AG (NYSE:UBS) latest ratings:

10/11/2017 Broker: Bank of America Old Rating: Neutral New Rating: Buy Upgrade

Since October 2, 2017, it had 0 insider purchases, and 13 sales for $41.72 million activity. Another trade for 50,000 shares valued at $4.18 million was sold by MARTIN JOHN C. Alton Gregg H sold $2.09 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, February 1. $401,566 worth of stock was sold by Washington Robin L on Wednesday, February 21. Shares for $8.02M were sold by Meyers James R. WILSON GAYLE E had sold 60,000 shares worth $4.68M on Friday, February 9.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on May, 1. They expect $1.59 EPS, down 27.73% or $0.61 from last year’s $2.2 per share. GILD’s profit will be $2.08 billion for 12.69 P/E if the $1.59 EPS becomes a reality. After $1.60 actual EPS reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -0.63% negative EPS growth.

Investors sentiment decreased to 0.8 in Q3 2017. Its down 0.23, from 1.03 in 2017Q2. It is negative, as 96 investors sold GILD shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Texas Permanent School Fund reported 0.38% stake. Invesco accumulated 0.53% or 17.81M shares. 23,147 are held by Appleton Ptnrs Ma. The Texas-based B T Mgmt Dba Alpha Mgmt has invested 1.31% in Gilead Sciences, Inc. (NASDAQ:GILD). Orrstown Fin Ser reported 510 shares. Moreover, Cognios Limited Com has 1.37% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 41,660 shares. Bp Plc reported 0.67% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). 22,907 were reported by Douglass Winthrop Advisors Ltd Liability Corp. Hendley & Co Inc accumulated 25,379 shares. Moreover, M&R Capital Mngmt Incorporated has 0.02% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 1,200 shares. Webster Bankshares N A holds 1,403 shares or 0.02% of its portfolio. Endurance Wealth Mngmt accumulated 26,160 shares. Lehman owns 37,753 shares. 93,077 were accumulated by Tt Int. Tower Research Capital Lc (Trc) reported 4,864 shares.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 21 have Buy rating, 0 Sell and 9 Hold. Therefore 70% are positive. Gilead Sciences has $137 highest and $7200 lowest target. $97.86’s average target is 21.23% above currents $80.72 stock price. Gilead Sciences had 126 analyst reports since July 29, 2015 according to SRatingsIntel. Mizuho initiated Gilead Sciences, Inc. (NASDAQ:GILD) rating on Tuesday, November 8. Mizuho has “Buy” rating and $88 target. On Thursday, February 11 the stock rating was initiated by Oppenheimer with “Outperform”. The rating was maintained by BMO Capital Markets on Thursday, July 27 with “Hold”. Jefferies reinitiated Gilead Sciences, Inc. (NASDAQ:GILD) rating on Tuesday, July 11. Jefferies has “Hold” rating and $80 target. Robert W. Baird maintained the shares of GILD in report on Friday, September 15 with “Buy” rating. The firm earned “Hold” rating on Tuesday, July 26 by Needham. The firm has “Hold” rating by Oppenheimer given on Thursday, December 21. Leerink Swann initiated the shares of GILD in report on Friday, February 5 with “Outperform” rating. The firm has “Hold” rating given on Monday, November 13 by Argus Research. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Stifel Nicolaus on Monday, November 14.

The stock decreased 0.11% or $0.02 during the last trading session, reaching $18.39. About 2.98 million shares traded or 17.77% up from the average. UBS Group AG (NYSE:UBS) has risen 14.86% since March 12, 2017 and is uptrending. It has underperformed by 1.84% the S&P500.

UBS Group AG, together with its subsidiaries, provides financial advice and solutions clients worldwide. The company has market cap of $69.24 billion. It operates through five divisions: Wealth Management, Wealth Management Americas, Personal & Corporate Banking, Asset Management, and Investment Bank. It has a 57.83 P/E ratio. The Wealth Management division offers advisory and financial services to wealthy private clients.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter: